COEGIN — Coegin Pharma AB Balance Sheet
0.000.00%
- SEK111.70m
- SEK92.02m
Annual balance sheet for Coegin Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | Interim Report | ARS | ARS | PRESS |
Standards: | SAS | — | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 16.6 | 25.7 | 3.82 | 5.55 | 19.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.35 | 4.5 | 2.75 | 0.499 | 0.989 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19.1 | 30.3 | 6.97 | 6.21 | 20.8 |
Net Property, Plant And Equipment | 0.002 | 0.002 | 0.485 | 0.302 | 0.148 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 19.1 | 30.3 | 29.2 | 15.4 | 27 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.43 | 10.3 | 8.23 | 8.68 | 1.78 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 2.43 | 10.3 | 8.23 | 8.68 | 1.78 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 16.7 | 20.1 | 21 | 6.75 | 25.3 |
Total Liabilities & Shareholders' Equity | 19.1 | 30.3 | 29.2 | 15.4 | 27 |
Total Common Shares Outstanding |